Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven P. Treon, M.D., Ph.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. K23CA087977 (TREON, STEVEN PETER) Sep 1, 2000 - Aug 31, 2005
    NIH/NCI
    NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, Meid K, Yang G. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915. PMID: 32302379.
    Citations:    
  2. Jiménez C, Chan GG, Xu L, Tsakmaklis N, Kofides A, Demos MG, Chen J, Liu X, Munshi M, Yang G, Castillo JJ, Wiestner A, García-Sanz R, Treon SP, Hunter ZR. Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. Br J Haematol. 2020 Jun; 189(6):1165-1170. PMID: 32103491.
    Citations:    
  3. Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, Demos M, Gustine J, Chan G, Munshi M, Tsakmaklis N, Chen JG, Kofides A, Sklavenitis-Pistofidis R, Bustoros M, Keezer A, Meid K, Patterson CJ, Sacco A, Roccaro A, Branagan AR, Yang G, Ghobrial IM, Castillo JJ. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 Apr 10; 38(11):1198-1208. PMID: 32083995.
    Citations:    
  4. Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Jimenez C, Chan GG, Hunter ZR, Palomba ML, Argyropoulos KV, Meid K, Keezer A, Gustine J, Dubeau T, Castillo JJ, Patterson CJ, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12. PMID: 32005797.
    Citations:    
  5. Castillo JJ, Itchaki G, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Leuk Lymphoma. 2020 Jun; 61(6):1388-1394. PMID: 31992103.
    Citations:    
  6. Liu X, Chen JG, Munshi M, Hunter ZR, Xu L, Kofides A, Tsakmaklis N, Demos MG, Guerrera ML, Chan GG, Jimenez C, Patterson CJ, Meid K, Keezer A, Castillo JJ, Treon SP, Yang G. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Adv. 2020 Jan 14; 4(1):141-153. PMID: 31935288.
    Citations:    
  7. Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 Jan 13. PMID: 31943341.
    Citations:    
  8. Castillo JJ, Gustine JN, Keezer A, Meid K, Flynn CA, Dubeau TE, Chan G, Chen J, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2019 Dec 23. PMID: 31868242.
    Citations:    
  9. Singer S, Tan SY, Dewan AK, Davids M, LaCasce AS, Treon SP, LeBoeuf NR. Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events. J Am Acad Dermatol. 2019 Dec 20. PMID: 31870917.
    Citations:    
  10. Sewastianik T, Guerrera ML, Adler K, Dennis PS, Wright K, Shanmugam V, Huang Y, Tanton H, Jiang M, Kofides A, Demos MG, Dalgarno A, Patel NA, Nag A, Pinkus GS, Yang G, Hunter ZR, Jarolim P, Munshi NC, Treon SP, Carrasco RD. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Adv. 2019 11 12; 3(21):3360-3374. PMID: 31698464.
    Citations:    
  11. Gustine JN, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Keezer A, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ. CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. Blood Adv. 2019 10 08; 3(19):2800-2803. PMID: 31570491.
    Citations:    
  12. Castillo JJ, Treon SP. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562. PMID: 31591468.
    Citations:    
  13. Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285. PMID: 31430829.
    Citations:    
  14. Bustoros M, Sklavenitis-Pistofidis R, Castillo JJ, Treon SP, Ghobrial IM. Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702. PMID: 31424980.
    Citations:    
  15. Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP. Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 Aug 01; 25(15):4860. PMID: 31371310.
    Citations:    
  16. Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881. PMID: 31343930.
    Citations:    
  17. Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE, Liu X, Demos MG, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Yang G, Hunter ZR, Treon SP. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363. PMID: 31267520.
    Citations:    
  18. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411. PMID: 30990729.
    Citations:    
  19. Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, Weinstock DM, Gray NS. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood. 2019 02 28; 133(9):952-961. PMID: 30545835.
    Citations:    Fields:    
  20. Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305. PMID: 30523119.
    Citations:    Fields:    
  21. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol. 2019 02; 184(4):558-569. PMID: 30506764.
    Citations:    Fields:    
  22. Cheng MP, Kusztos AE, Gustine JN, Dryden-Peterson SL, Dubeau TE, Woolley AE, Hammond SP, Baden LR, Treon SP, Castillo JJ, Issa NC. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790. PMID: 30460682.
    Citations:    Fields:    
  23. Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946. PMID: 30401751.
    Citations:    
  24. Babwah A, Gustine J, Meid K, Dubeau T, Xu L, Yang G, Hunter ZR, Treon SP, Castillo JJ. Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802. PMID: 30407630.
    Citations:    Fields:    
  25. Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612. PMID: 30366921.
    Citations:    Fields:    
  26. Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M. Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018; 13(10):e0204589. PMID: 30286096.
    Citations:    Fields:    
  27. Castillo JJ, Kastritis E, Treon SP. Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematol Oncol Clin North Am. 2018 10; 32(5):xiii-xiv. PMID: 30190026.
    Citations:    Fields:    
  28. Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter Z, Anderson KC, Treon SP, Munshi NC, Fulciniti M. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 01 01; 25(1):369-377. PMID: 30206161.
    Citations:    Fields:    
  29. Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ, Xu L. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245. PMID: 30183082.
    Citations: 1     Fields:    
  30. Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res. 2018 12 15; 24(24):6408-6420. PMID: 30126942.
    Citations:    Fields:    
  31. Treon SP, Xu L, Liu X, Hunter ZR, Yang G, Castillo JJ. Genomic Landscape of Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):745-752. PMID: 30190014.
    Citations:    Fields:    
  32. Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, Demos M, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Chan G, Dubeau T, Raje N, Yee A, O'Donnell E, Hunter ZR, Castillo JJ. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761. PMID: 30044692.
    Citations: 1     Fields:    
  33. Castillo JJ, Treon SP. Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):811-820. PMID: 30190019.
    Citations:    Fields:    
  34. Treon SP, Castillo JJ. The real world of Waldenström's macroglobulinaemia. Lancet Haematol. 2018 07; 5(7):e275-e276. PMID: 29958567.
    Citations:    Fields:    Translation:Humans
  35. Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 Jun 21; 378(25):2399-2410. PMID: 29856685.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  36. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Xu L, Yang G, Hunter ZR, Advani R, Palomba L, Treon SP. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468. PMID: 29773590.
    Citations:    Fields:    
  37. Castillo JJ, Dubeau T, Kofides A, Demos MG, Tsakmaklis N, Xu L, Hunter ZR, Treon SP. Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia. Am J Hematol. 2018 May 14. PMID: 29756293.
    Citations:    Fields:    
  38. Castillo JJ, Gustine JN, Treon SP. Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. JAMA Oncol. 2018 05 01; 4(5):744-745. PMID: 29392274.
    Citations:    Fields:    
  39. Castillo JJ, Meid K, Gustine JN, Dubeau T, Severns P, Hunter ZR, Yang G, Xu L, Treon SP. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. Clin Cancer Res. 2018 07 15; 24(14):3247-3252. PMID: 29661775.
    Citations:    Fields:    
  40. Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR. MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica. 2018 09; 103(9):e408-e411. PMID: 29599202.
    Citations: 1     Fields:    
  41. Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Xu L, Yang G, Hunter ZR, Treon SP. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol. 2019 03; 184(6):1011-1014. PMID: 29532913.
    Citations:    Fields:    
  42. Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid K, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018 05 03; 131(18):2047-2059. PMID: 29496671.
    Citations: 2     Fields:    
  43. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, Yang G, Hunter ZR, Treon SP. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018 04; 181(1):77-85. PMID: 29468652.
    Citations: 1     Fields:    
  44. Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Treon SP. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310. PMID: 29472352.
    Citations:    Fields:    
  45. Gustine JN, Meid K, Dubeau T, Severns P, Hunter ZR, Guang Y, Xu L, Treon SP, Castillo JJ. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517. PMID: 29280186.
    Citations: 2     Fields:    
  46. Mancek-Keber M, Lainšcek D, Bencina M, Chen JG, Romih R, Hunter ZR, Treon SP, Jerala R. Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling. Blood. 2018 04 12; 131(15):1720-1729. PMID: 29358175.
    Citations: 3     Fields:    
  47. Castillo JJ, Gustine JN, Meid K, Xu L, Hunter ZR, Treon SP. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 03; 93(3):E69-E71. PMID: 29218718.
    Citations:    Fields:    
  48. Castillo JJ, Treon SP. Toward personalized treatment in Waldenström macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370. PMID: 29222280.
    Citations:    Fields:    Translation:Humans
  49. Treon SP, Castillo JJ. What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Adv. 2017 Nov 28; 1(25):2486-2490. PMID: 29296899.
    Citations:    
  50. Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, Meid K, Guerrera ML, Munshi M, Chan G, Chen J, Kofides A, Patterson CJ, Yang G, Liu X, Severns P, Dubeau T, Hunter ZR, Castillo JJ. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018 02; 180(3):374-380. PMID: 29181840.
    Citations: 3     Fields:    Translation:Humans
  51. Huang HT, Dobrovolsky D, Paulk J, Yang G, Weisberg EL, Doctor ZM, Buckley DL, Cho JH, Ko E, Jang J, Shi K, Choi HG, Griffin JD, Li Y, Treon SP, Fischer ES, Bradner JE, Tan L, Gray NS. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chem Biol. 2018 01 18; 25(1):88-99.e6. PMID: 29129717.
    Citations: 5     Fields:    Translation:HumansCells
  52. Vos JM, Tsakmaklis N, Patterson CJ, Meid K, Castillo JJ, Brodsky P, Ganz T, Pals ST, Kersten MJ, Xu L, Yang G, Treon SP, Hunter ZR. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica. 2017 11; 102(11):e452-e455. PMID: 28798070.
    Citations: 1     Fields:    Translation:Humans
  53. Olszewski AJ, Chen C, Gutman R, Treon SP, Castillo JJ. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. Br J Haematol. 2017 10; 179(1):106-115. PMID: 28677830.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  54. Castillo JJ, Hunter ZR, Yang G, Treon SP. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. Expert Rev Hematol. 2017 08; 10(8):739-744. PMID: 28617062.
    Citations:    Fields:    Translation:HumansAnimalsCells
  55. Sacco A, Fenotti A, Affò L, Bazzana S, Russo D, Presta M, Malagola M, Anastasia A, Motta M, Patterson CJ, Rossi G, Imberti L, Treon SP, Ghobrial IM, Roccaro AM. The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. Oncotarget. 2017 May 23; 8(21):35435-35444. PMID: 28423722.
    Citations:    Fields:    Translation:Humans
  56. Gustine JN, Meid K, Dubeau T, Hunter ZR, Xu L, Yang G, Ghobrial IM, Treon SP, Castillo JJ. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725. PMID: 28485115.
    Citations: 3     Fields:    Translation:Humans
  57. Nielsen JS, Chang AR, Wick DA, Sedgwick CG, Zong Z, Mungall AJ, Martin SD, Kinloch NN, Ott-Langer S, Brumme ZL, Treon SP, Connors JM, Gascoyne RD, Webb JR, Berry BR, Morin RD, Macpherson N, Nelson BH. Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology. 2017; 6(7):e1321184. PMID: 28811957.
    Citations: 3     
  58. Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo JJ, Furman RR, Hunter ZR, Treon SP. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017 05 04; 129(18):2519-2525. PMID: 28235842.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  59. D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017 03; 176(5):728-742. PMID: 28198999.
    Citations: 6     Fields:    Translation:Humans
  60. Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001. PMID: 28294689.
    Citations: 6     Fields:    Translation:HumansCells
  61. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 02; 15(2):230-269. PMID: 28188192.
    Citations: 14     Fields:    Translation:Humans
  62. Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250. PMID: 27956157.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  63. Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunter ZR, Yang G, Patterson CJ, Gustine J, Castillo JJ, Matous J, Ghobrial IM. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404. PMID: 27836860.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  64. Gustine JN, Meid K, Hunter ZR, Xu L, Treon SP, Castillo JJ. MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. Br J Haematol. 2018 02; 180(4):578-581. PMID: 27748515.
    Citations: 3     Fields:    Translation:Humans
  65. Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica. 2017 01; 102(1):43-51. PMID: 27758817.
    Citations: 6     Fields:    Translation:Humans
  66. Sacco A, Fenotti A, Bazzana S, Imberti L, Rossi G, Patterson CJ, Treon SP, Ghobrial IM, Roccaro AM. Epigenomics in Waldenstrom's macroglobulinaemia. Best Pract Res Clin Haematol. 2016 06; 29(2):156-160. PMID: 27825461.
    Citations:    Fields:    Translation:HumansAnimalsCells
  67. Castillo JJ, Hunter ZR, Yang G, Argyropoulos K, Palomba ML, Treon SP. Future therapeutic options for patients with Waldenström macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215. PMID: 27825467.
    Citations: 1     Fields:    Translation:Humans
  68. Castillo JJ, Gustine JN, Meid K, Dubeau T, Yang G, Xu L, Hunter ZR, Treon SP. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004. PMID: 27562445.
    Citations: 4     Fields:    Translation:Humans
  69. Olszewski AJ, Treon SP, Castillo JJ. Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. Oncologist. 2016 Nov; 21(11):1377-1386. PMID: 27473042.
    Citations: 4     Fields:    
  70. Vos JM, Gustine J, Rennke HG, Hunter Z, Manning RJ, Dubeau TE, Meid K, Minnema MC, Kersten MJ, Treon SP, Castillo JJ. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630. PMID: 27468978.
    Citations: 8     Fields:    Translation:Humans
  71. Castillo JJ, Gustine J, Meid K, Dubeau T, Hunter ZR, Treon SP. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5. PMID: 27415417.
    Citations: 5     Fields:    Translation:Humans
  72. Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 09 08; 128(10):1321-8. PMID: 27432877.
    Citations: 9     Fields:    Translation:Humans
  73. Mason C, Savona S, Rini JN, Castillo JJ, Xu L, Hunter ZR, Treon SP, Allen SL. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341. PMID: 27409073.
    Citations: 7     Fields:    Translation:Humans
  74. Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, Varettoni M, Dimopoulos MA, Treon SP, Kastritis E. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br J Haematol. 2016 10; 175(1):77-86. PMID: 27378193.
    Citations: 6     Fields:    Translation:Humans
  75. Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos JM, Liu X, Chen J, Manning RJ, Chen JG, Brodsky P, Patterson CJ, Gustine J, Dubeau T, Castillo JJ, Anderson KC, Munshi NM, Treon SP. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016 08 11; 128(6):827-38. PMID: 27301862.
    Citations: 8     Fields:    Translation:HumansCells
  76. Castillo JJ, Palomba ML, Advani R, Treon SP. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Ther Adv Hematol. 2016 Aug; 7(4):179-86. PMID: 27493708.
    Citations: 4     
  77. Cea M, Cagnetta A, Acharya C, Acharya P, Tai YT, Yang C, Lovera D, Soncini D, Miglino M, Fraternali-Orcioni G, Mastracci L, Nencioni A, Montecucco F, Monacelli F, Ballestrero A, Hideshima T, Chauhan D, Gobbi M, Lemoli RM, Munshi N, Treon SP, Anderson KC. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109. PMID: 27287071.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  78. Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, Hunter ZR, Gray N, Treon SP. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52. PMID: 27143257.
    Citations: 4     Fields:    Translation:HumansCells
  79. Gustine JN, Meid K, Dubeau TE, Treon SP, Castillo JJ. Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3. PMID: 26994323.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  80. Liu X, Hunter ZR, Xu L, Chen J, Chen JG, Tsakmaklis N, Patterson CJ, Castillo JJ, Buhrlage S, Gray N, Treon SP, Yang G. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813. PMID: 27073043.
    Citations: 1     Fields:    Translation:HumansCells
  81. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 04; 14(4):389-400. PMID: 27059188.
    Citations: 13     Fields:    Translation:Humans
  82. Castillo JJ, Ghobrial IM, Treon SP. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701. PMID: 26980069.
    Citations: 1     Fields:    Translation:Humans
  83. Gustine J, Meid K, Xu L, Hunter ZR, Castillo JJ, Treon SP. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824. PMID: 26936399.
    Citations: 4     Fields:    Translation:HumansCells
  84. Roccaro AM, Sacco A, Shi J, Chiarini M, Perilla-Glen A, Manier S, Glavey S, Aljawai Y, Mishima Y, Kawano Y, Moschetta M, Correll M, Improgo MR, Brown JR, Imberti L, Rossi G, Castillo JJ, Treon SP, Freedman ML, Van Allen EM, Hide W, Hiller E, Rainville I, Ghobrial IM. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606. PMID: 26903547.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  85. Argyropoulos KV, Vogel R, Ziegler C, Altan-Bonnet G, Velardi E, Calafiore M, Dogan A, Arcila M, Patel M, Knapp K, Mallek C, Hunter ZR, Treon SP, van den Brink MR, Palomba ML. Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia. 2016 05; 30(5):1116-25. PMID: 26867669.
    Citations: 4     Fields:    Translation:HumansCells
  86. Fulciniti M, Amodio N, Bandi RL, Cagnetta A, Samur MK, Acharya C, Prabhala R, D'Aquila P, Bellizzi D, Passarino G, Adamia S, Neri A, Hunter ZR, Treon SP, Anderson KC, Tassone P, Munshi NC. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016 Jan 15; 6:e380. PMID: 26771806.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  87. Castillo JJ, Treon SP, Davids MS. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9. PMID: 26841015.
    Citations: 5     Fields:    Translation:HumansCells
  88. Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15. PMID: 26686858.
    Citations: 8     Fields:    Translation:Humans
  89. Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44. PMID: 26659815.
    Citations: 13     Fields:    Translation:Humans
  90. de Rooij MF, Kuil A, Kraan W, Kersten MJ, Treon SP, Pals ST, Spaargaren M. Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia. Haematologica. 2016 Mar; 101(3):e111-5. PMID: 26635033.
    Citations: 7     Fields:    Translation:HumansCells
  91. Nielsen JS, Sedgwick CG, Shahid A, Zong Z, Brumme ZL, Yu S, Liu L, Kroeger DR, Treon SP, Connors JM, Gascoyne RD, Berry BR, Marra MA, Morin RD, Macpherson N, Nelson BH. Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clin Cancer Res. 2016 05 01; 22(9):2226-36. PMID: 26631611.
    Citations: 7     Fields:    Translation:HumansCells
  92. Castillo JJ, Kanan S, Meid K, Manning R, Hunter ZR, Treon SP. Rituximab intolerance in patients with Waldenström macroglobulinaemia. Br J Haematol. 2016 08; 174(4):645-8. PMID: 26523929.
    Citations: 3     Fields:    Translation:Humans
  93. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435. PMID: 26553768.
    Citations: 7     Fields:    Translation:Humans
  94. Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med. 2015 Aug 06; 373(6):584-6. PMID: 26244327.
    Citations: 36     Fields:    Translation:Humans
  95. Ghobrial IM, Redd R, Armand P, Banwait R, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro AM, Perilla-Glen A, Noonan K, MacNabb M, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Weller E, Treon SP. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec; 29(12):2338-46. PMID: 26139427.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  96. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug; 90(8):696-701. PMID: 25963924.
    Citations: 1     Fields:    Translation:Humans
  97. Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD. The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80. PMID: 26005854.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  98. Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2015 Aug 06; 126(6):721-32. PMID: 26002963.
    Citations: 22     Fields:    Translation:HumansCells